Yükleniyor... / Loading...
Selumetinib in Cancers With BRAF Mutations
Bu çalışma, tümörlerinde BRAF geni değişikliği (V600E veya diğer aktifleştirici BRAF mutasyonları) bulunan kanser hastalarında Selumetinib ilacını değerlendirmiştir. Çalışmaya, histolojik olarak doğrulanmış metastatik veya ameliyatla çıkarılamayan solid tümörü olan, ölçülebilir hastalığı bulunan hastalar katılabilmiştir (melanom hastaları hariç). National Cancer Institute (NCI) tarafından yürütülen çalışma Faz 2 aşamasında yürütülmüş ve tamamlanmıştır.
Yukarıdaki özet, resmî kaydın sade dile aktarılmış halidir. Orijinal İngilizce başlık referans için gösterilir.
Kriterler ClinicalTrials.gov kaydından orijinal İngilizce haliyle alınmıştır. Uygunluk kararını yalnızca deneyi yürüten ekip verebilir.
Inclusion Criteria: * Ability to understand and willingness to sign a written informed consent document * Histologically confirmed metastatic or unresectable solid tumor * Results from tumor tissue analysis that show a glutamic acid-for-valine substitution at amino acid position 600 in the BRAF gene (V600E) or other activating BRAF mutation, as determined by high-throughput genotyping * Patients may have received any number of prior systemic treatments for their cancer * At least one measurable site of disease by CT, according to standard RECIST criteria 1.0 * ECOG performance status 0-1 * Absolute neutrophil count \> 1500 per cubic mm * Platelet count \> 100,000 per cubic mm * Hemoglobin \> 9 g/dl * Serum bilirubin \< 1.5 x upper limit of normal * Serum AST and ALT \< 2.5 x upper limit of normal (=\< 5 x upper limit of normal, for liver metastases) * Serum creatinine \< 1.5 x upper limit of normal * For women of childbearing potential, negative serum pregnancy test and use of physician-approved method of birth control throughout the study Exclusion Criteria: * Estimated life expectancy \> 12 weeks * Patients with melanoma * Have received chemotherapy or radiotherapy within 4 weeks prior to entering the study (6 weeks for nitrosoureas or mitomycin C), or a targeted therapy within 2 weeks prior to entering the study * Have not recovered from adverse events due to agents previously administered (CTCAE v3 grade 1 or baseline) * Currently receiving other investigational agents * Known brain metastases, unless treated and stable off of corticosteroids for at least four weeks * History of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD6244 * Prior treatment with a selective inhibitor of RAF or MEK (e.g., RAF265); (note: prior sorafenib is allowed) * Uncontrolled intercurrent illness, including but not limited to: * Clinically significant active infection * Symptomatic congestive heart failure, unstable angina pectoris, and/or cardiac arrhythmia other than atrial fibrillation * Psychiatric illness/social situations that would limit compliance with study requirements * Refractory nausea or vomiting, swallowing disorder, or malabsorption syndrome that would interfere with swallowing or absorbing the study medication * Pregnant and/or breast-feeding women * Previous or concurrent malignancy, except for the following circumstances: * Disease-free for at least three years and deemed by investigator to be at low risk for recurrence of that malignancy * Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin) * History of solid organ transplantation or other condition requiring the use of immunosuppressive medications * Uncontrolled hypertension (systolic BP \>= 150 or diastolic BP \>= 100 that cannot be controlled with medications) * A mean left ventricular ejection fraction (LVEF) less than 45%